Women’s Health Today—May 27, 2026

This biweekly Women’s Health video recap highlights regulatory progress, late-stage clinical data, therapeutic expansion, AI initiatives, and evolving diagnostic frameworks across breast, gynecologic, and cardiovascular health.

Dive deeper

In Today’s Newsletter

💊 Enhertu expands into HER2-positive early breast cancer [1] [US • 15 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-two-her2-early-bc-settings.html
Context: Enhertu (trastuzumab deruxtecan; AstraZeneca and Daiichi Sankyo) was reviewed for DESTINY-Breast11 and DESTINY-Breast05.
Key point: FDA approved Enhertu for neoadjuvant Stage II or III HER2-positive breast cancer and adjuvant residual invasive disease.
Implication: May influence prescriber choice and payer reviews pending full data.

🎯 Datroway approved for 1st-line metastatic TNBC [2] [US • 22 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-approved-in-us-for-1l-triple-negative-bc.html
Context: Datroway (datopotamab deruxtecan; AstraZeneca and Daiichi Sankyo) was evaluated in TROPION-Breast02.
Key point: FDA approved Datroway for unresectable or metastatic TNBC patients who are not PD-1/PD-L1 inhibitor candidates.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Camizestrant gets EU CHMP backing in ESR1-mutated breast cancer [3] [EU • 22 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/camizestrant-recommended-for-breast-cancer-in-eu.html
Context: Camizestrant (AstraZeneca; oral SERD) plus a CDK4/6 inhibitor was assessed in SERENA-6.
Key point: CHMP recommended approval for ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation before progression.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Trodelvy receives CHMP positive opinion in 1st-line TNBC [4] [EU • 22 May 2026]

https://www.gilead.com/news/news-details/2026/gilead-receives-chmp-positive-opinion-for-trodelvy-in-first-line-metastatic-triple-negative-breast-cancer-for-patients-not-candidates-for-pd-l1-inhibitors
Context: Trodelvy (sacituzumab govitecan; Gilead) was evaluated in ASCENT-03.
Key point: CHMP recommended Trodelvy monotherapy for 1st-line unresectable locally advanced or metastatic TNBC in PD-(L)1-ineligible patients.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Sac-TMT hits OS and PFS endpoints in endometrial cancer [5] [US • 18 May 2026]

https://www.merck.com/news/merck-announces-trofuse-005-trial-evaluating-sacituzumab-tirumotecan-sac-tmt-met-primary-endpoints-of-overall-survival-os-and-progression-free-survival-pfs-in-certain-patients-with-advanced-or-r/
Context: Sacituzumab tirumotecan (sac-TMT; Merck and Kelun-Biotech) was tested in Phase 3 TroFuse-005.
Key point: The trial met OS and PFS primary endpoints versus chemotherapy in post-platinum, post-PD-1/L1 advanced or recurrent endometrial cancer.
Implication: May influence prescriber choice and payer reviews pending full data.

🏷️ PCOS renamed PMOS after global review [6] [Global • 12 May 2026]

https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change
Context: Polyendocrine Metabolic Ovarian Syndrome (PMOS) replaces Polycystic Ovary Syndrome (PCOS) after a global consultation.
Key point: More than 50 organizations backed the change to reflect hormonal, metabolic, mental health, skin, and reproductive effects.
Implication: May expand screening, initiation, and follow-up at scale.

🤖 Women’s Health AI Consortium launches standards push [7] [US • 13 May 2026]

https://www.businesswire.com/news/home/20260512079508/en/Health-Leaders-Join-Forces-to-Launch-First-of-Its-Kind-Womens-Health-AI-Consortium
Context: Willow, Ema EQ, Clue, Oura, Carrot Fertility, and others formed the Women’s Health AI Consortium.
Key point: The group will set shared benchmarks, ethical standards, and transparent evaluation methods for AI in women’s health.
Implication: Signals pipeline investment and modality expansion.

❤️ Women’s Heart Health Summit highlights missed risk [8] [US • 20 May 2026]

https://www.fiercehealthcare.com/providers/missed-risk-womens-heart-health-summit-explores-gaps-research-treatment
Context: Hello Heart hosted the Women’s Heart Health Summit with clinicians, researchers, employers, and advocates.
Key point: Speakers highlighted gaps in women’s cardiovascular research, risk detection, cardio-obstetrics, home monitoring, and AI implementation.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why It Matters

Breast cancer treatment sequencing is shifting earlier, especially for HER2-positive disease and 1st-line metastatic TNBC.
TROP2 ADC competition is intensifying across breast and gynecologic cancers, with Datroway, Trodelvy, and sac-TMT all in focus.
ctDNA-guided therapy switching is moving closer to routine use in ER-positive, HER2-negative advanced breast cancer.
Women’s health infrastructure is broadening beyond therapeutics into naming, AI governance, and cardiovascular risk detection.
PMOS terminology could reshape diagnosis, education, and guideline implementation through 2028.

📚 View the full Women’s health archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What changed for Enhertu in HER2-positive early breast cancer?

FDA approved Enhertu (trastuzumab deruxtecan) in both neoadjuvant and adjuvant HER2-positive early breast cancer settings, based on DESTINY-Breast11 and DESTINY-Breast05. [1]

How is Datroway positioned in metastatic TNBC?

Datroway (datopotamab deruxtecan) is approved in the US for 1st-line unresectable or metastatic TNBC patients who are not candidates for PD-1/PD-L1 inhibitors. [2]

What is notable about camizestrant in SERENA-6?

Camizestrant plus a CDK4/6 inhibitor received a CHMP positive opinion for ER-positive, HER2-negative advanced breast cancer after emergent ESR1 mutation detection and before progression. [3]

What did CHMP recommend for Trodelvy?

CHMP recommended Trodelvy monotherapy for adult patients with 1st-line unresectable locally advanced or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitors. [4]

What did Merck report for sac-TMT?

Merck said sacituzumab tirumotecan met OS and PFS primary endpoints in Phase 3 TroFuse-005 for certain advanced or recurrent endometrial cancer patients after platinum and PD-1/L1 therapy. [5]

Why was PCOS renamed PMOS?

The Endocrine Society and global partners said the new name better reflects the endocrine, metabolic, and broader health features of the condition, rather than focusing on ovarian cysts. [6]

Entities / Keywords

Enhertu, trastuzumab deruxtecan, T-DXd, AstraZeneca, Daiichi Sankyo, HER2-positive early breast cancer, DESTINY-Breast11, DESTINY-Breast05
Datroway, datopotamab deruxtecan, Dato-DXd, TROP2 ADC, TNBC, TROPION-Breast02
Camizestrant, oral SERD, AstraZeneca, CDK4/6 inhibitor, ESR1 mutation, SERENA-6, ER-positive breast cancer
Trodelvy, sacituzumab govitecan, Gilead, ASCENT-03, metastatic TNBC
Sacituzumab tirumotecan, sac-TMT, Merck, MSD, Kelun-Biotech, TroFuse-005, endometrial cancer
PMOS, PCOS, Polyendocrine Metabolic Ovarian Syndrome, Endocrine Society, Monash University
Women’s Health AI Consortium, Willow, Ema EQ, Clue, Oura, Carrot Fertility
Women’s Heart Health Summit, Hello Heart, American College of Cardiology, cardio-obstetrics